Literature DB >> 15686972

Oesophageal strictures in cats associated with doxycycline therapy.

Alexander James German1, Martha Jane Cannon, Charlotte Dye, Malcolm John Booth, Geoffrey Robert Pearson, Caroline Anne Reay, Timothy John Gruffydd-Jones.   

Abstract

Four cases of oesophageal stricture subsequent to doxycycline administration are reported. All cases were young to middle age (median age 3 years; range 1-7 years), and either domestic shorthair or domestic longhair breed. In all cases the predominant clinical sign was regurgitation, which developed at variable times after doxycycline administration. In all cases the reason for doxycycline use was treatment or prophylaxis of suspected infections (Mycoplasma haemofelis, Chlamydophila felis or Bordetella bronchiseptica), and the duration of therapy was variable. In one case the stricture was definitively diagnosed at post mortem examination, in the three other cases, definitive diagnosis was by endoscopy. Balloon dilation was successful in the three cases that were treated. This is the largest case series, to date, of oesophageal disease in cats associated with doxycycline administration. Caution should be exercised when administering oral medication to cats, especially doxycycline, and should be accompanied either by a water or food swallow.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686972     DOI: 10.1016/j.jfms.2004.04.001

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  10 in total

1.  Intralesional steroid injection after endoluminal esophageal stricture dilatation in a cat.

Authors:  María Cecilia Ricart; Sergio Rodriguez; Guadalupe Dova
Journal:  Open Vet J       Date:  2022-03-25

Review 2.  Haemotropic mycoplasmas: what's their real significance in cats?

Authors:  Séverine Tasker
Journal:  J Feline Med Surg       Date:  2010-05       Impact factor: 2.015

3.  Prospective evaluation of an indwelling esophageal balloon dilatation feeding tube for treatment of benign esophageal strictures in dogs and cats.

Authors:  Desmond K Tan; Chick Weisse; Allyson Berent; Kenneth E Lamb
Journal:  J Vet Intern Med       Date:  2018-02-20       Impact factor: 3.333

4.  Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases.

Authors:  M R Lappin; J Blondeau; D Boothe; E B Breitschwerdt; L Guardabassi; D H Lloyd; M G Papich; S C Rankin; J E Sykes; J Turnidge; J S Weese
Journal:  J Vet Intern Med       Date:  2017-02-10       Impact factor: 3.333

5.  Antimicrobial prescriptions in cats in Switzerland before and after the introduction of an online antimicrobial stewardship tool.

Authors:  Alina Hubbuch; Kira Schmitt; Claudia Lehner; Sonja Hartnack; Simone Schuller; Gertraud Schüpbach-Regula; Meike Mevissen; Ruth Peter; Cedric Müntener; Hanspeter Naegeli; Barbara Willi
Journal:  BMC Vet Res       Date:  2020-07-03       Impact factor: 2.741

Review 6.  Lower respiratory tract infections in cats: reaching beyond empirical therapy.

Authors:  Susan F Foster; Patricia Martin
Journal:  J Feline Med Surg       Date:  2011-05       Impact factor: 2.015

7.  First feline case of otodectosis in the Republic of Korea and successful treatment with imidacloprid/moxidectin topical solution.

Authors:  Ah-Jin Ahn; Dae-Sung Oh; Kyu-Sung Ahn; Sung-Shik Shin
Journal:  Korean J Parasitol       Date:  2013-02-18       Impact factor: 1.341

8.  Imaging evaluation of dogs and cats with Dysphagia.

Authors:  Rachel E Pollard
Journal:  ISRN Vet Sci       Date:  2012-10-31

9.  Obstructive fibrinous tracheal pseudomembrane in a cat.

Authors:  Ran Nivy; Ori Brenner; Vered Shub; Yaron Bruchim
Journal:  J Vet Intern Med       Date:  2020-10-24       Impact factor: 3.333

10.  The use of Savary-Gilliard dilators in the treatment of an oesophageal stricture in a cat.

Authors:  Ewa Kaczmar; Krystyna Makowska; Andrzej Rychlik
Journal:  Vet Res Commun       Date:  2022-02-02       Impact factor: 2.816

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.